Literature DB >> 12740575

NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.

Daniel D Billadeau1, Jadee L Upshaw, Renee A Schoon, Christopher J Dick, Paul J Leibson.   

Abstract

The immune recognition receptor complex NKG2D-DAP10 on natural killer cells is stimulated by specific ligands carried on virus-infected and malignant cells. Because DAP10 does not have an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic tail, its ability to trigger killing has been debated. Here we show that a crucial Tyr-Ile-Asn-Met amino acid motif in the cytoplasmic tail of DAP10 couples receptor stimulation to the downstream activation of phosphatidylinositol 3-kinase, Vav1, Rho family GTPases and phospholipase C. Unlike that of ITAM-containing receptors, the activation of NKG2D-DAP10 proceeds independently of Syk family protein tyrosine kinases. Yet the signals initiated by NKG2D-DAP10 are fully capable of inducing killing. Our findings identify a previously unknown mechanism by which receptor complexes that lack ITAM motifs can trigger lymphocyte activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12740575     DOI: 10.1038/ni929

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  128 in total

1.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion.

Authors:  Yenan T Bryceson; Michael E March; Hans-Gustaf Ljunggren; Eric O Long
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

3.  NKG2D-DAP10 signaling recruits EVL to the cytotoxic synapse to generate F-actin and promote NK cell cytotoxicity.

Authors:  Katelynn M Wilton; Brittany L Overlee; Daniel D Billadeau
Journal:  J Cell Sci       Date:  2019-07-18       Impact factor: 5.285

4.  JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity.

Authors:  Changlin Li; Baoxue Ge; Matthew Nicotra; Joel N H Stern; Hernan D Kopcow; Xi Chen; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

5.  Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity.

Authors:  Xi Chen; Prachi P Trivedi; Baoxue Ge; Konrad Krzewski; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-29       Impact factor: 11.205

Review 6.  Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease.

Authors:  James O J Davies; Kate Stringaris; A John Barrett; Katayoun Rezvani
Journal:  Cytotherapy       Date:  2014-05-20       Impact factor: 5.414

Review 7.  Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy.

Authors:  Kushal Prajapati; Cynthia Perez; Lourdes Beatriz Plaza Rojas; Brianna Burke; Jose A Guevara-Patino
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

8.  Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling.

Authors:  Ashley Mentlik James; Hsiang-Ting Hsu; Prachi Dongre; Gulbu Uzel; Emily M Mace; Pinaki P Banerjee; Jordan S Orange
Journal:  Blood       Date:  2013-02-04       Impact factor: 22.113

Review 9.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

10.  A truncated human NKG2D splice isoform negatively regulates NKG2D-mediated function.

Authors:  Cynthia L Baldwin; Taku Kambayashi; Mobin A Karimi; Oscar Aguilar; Baixiang Zou; Michael H Bachmann; James R Carlyle
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.